GAP43

Growth associated protein 43

Score: 0.483 Price: $0.48 Undruggable Druggability Status: active Wiki: GAP43

🧠 Neurodegeneration

HYPOTHESES

PAPERS

KG EDGES

120

DEBATES

3D Protein Structure

🧬 GAP43 — PDB 1B4C Click to expand

Experimental structure from RCSB PDB | Powered by Mol*

Druggability & Clinical Context

Druggability

Undruggable

Score: 0.21

Clinical Stage

Approved

Target Class

Structural Protein

Safety

0.40

Druggability Analysis

Drug Development0.70

Structural Tractability0.30

Target Class0.50

Safety Profile0.40

Key Metrics

PDB Structures:

Known Drugs:

Approved:

In Clinical Trials:

Drug Pipeline (4 compounds)

1 Preclinical

Therapeutic Areas:

Alzheimer's disease and cognitive decline Traumatic brain injury and neurotrauma Spinal cord injury and axonal regeneration Age-related neurodegeneration Peripheral nerve injury and neuropathic conditions Stroke recovery and neuroplasticity enhancement

Druggability Rationale: Despite its critical role in neuronal plasticity, GAP43 remains challenging to drug directly due to its intrinsically disordered protein structure and membrane-associated localization. While preclinical agents like PACAP and BDNF show promise in modulating GAP43-related pathways, the lack of a well-defined binding pocket and the protein's complex phosphorylation-dependent mechanisms make traditional small molecule targeting difficult. Future druggability strategies may require innovative approaches such as phosphorylation mimetics, protein engineering, or indirect modulators that enhance GAP43 expression or membrane translocation in neurodegenerative contexts.

Mechanism: Drugs targeting GAP43 would enhance axonal growth cone formation and synaptic plasticity by promoting phosphorylation or membrane translocation of GAP43, thereby facilitating neurite outgrowth and synapse formation. Alternatively, agents could upregulate GAP43 expression to restore neuronal connectivity and compensate for age-related decline in neurodegenerative conditions.

Drug Pipeline (4 compounds)

1 Preclinical

Known Drugs:

Pituitary Adenylyl Cyclase-Activating Peptide (PACAP) (preclinical) — Neuronal growth and synaptic plasticity enhancement

BDNF (Brain-Derived Neurotrophic Factor) (phase1) — Neurodegenerative diseases, traumatic brain injury

Chondroitinase ABC (research) — Axonal regeneration, spinal cord injury

NSF127 (phase2) — Alzheimer's disease, cognitive decline

Structural Data:

PDB —AlphaFold ✓Cryo-EM —

UniProt: P17677

Binding Pocket Analysis:

No characterized binding pockets have been identified; GAP43's intrinsically disordered nature precludes conventional ATP or allosteric binding sites typical of druggable proteins. Therapeutic targeting relies instead on protein-protein interaction surfaces for CALMODULIN binding and phosphorylation sites (PKC, PKA) rather than discrete ligand-binding pockets, making it better suited for biologics (peptides, proteins, antibodies) than small molecule modulation.

🧬 3D Protein Structure

🧬 GAP43 — PDB 1B4C Click to expand interactive 3D viewer

Experimental structure from RCSB PDB | Powered by Mol* | Rotate: click+drag | Zoom: scroll

Selectivity & Safety Considerations

GAP43 selectivity is less challenging than typical enzyme targets due to its structural protein classification with no enzymatic active sites; however, off-target effects remain a concern when using indirect modulators (e.g., PACAP or BDNF agonists) that engage multiple signaling pathways. Antibody-based or peptide approaches offer inherent selectivity advantages over small molecules given GAP43's unique epitope regions.